JP2010528035A - イオンチャネル調節物質およびその使用 - Google Patents

イオンチャネル調節物質およびその使用 Download PDF

Info

Publication number
JP2010528035A
JP2010528035A JP2010509512A JP2010509512A JP2010528035A JP 2010528035 A JP2010528035 A JP 2010528035A JP 2010509512 A JP2010509512 A JP 2010509512A JP 2010509512 A JP2010509512 A JP 2010509512A JP 2010528035 A JP2010528035 A JP 2010528035A
Authority
JP
Japan
Prior art keywords
optionally substituted
pain
independently
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010509512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528035A5 (enExample
Inventor
エスター マーティンボロー，
ティモシー ニューバート，
タラ ウィットニー，
デニール レーステン，
タラ ハンプトン，
ニコル ジマーマン，
アンドレアス ターミン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2010528035A publication Critical patent/JP2010528035A/ja
Publication of JP2010528035A5 publication Critical patent/JP2010528035A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/53—X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
JP2010509512A 2007-05-25 2008-05-21 イオンチャネル調節物質およびその使用 Pending JP2010528035A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93172207P 2007-05-25 2007-05-25
PCT/US2008/064314 WO2008147797A2 (en) 2007-05-25 2008-05-21 Ion channel modulators and methods of use

Publications (2)

Publication Number Publication Date
JP2010528035A true JP2010528035A (ja) 2010-08-19
JP2010528035A5 JP2010528035A5 (enExample) 2012-06-07

Family

ID=39876632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010509512A Pending JP2010528035A (ja) 2007-05-25 2008-05-21 イオンチャネル調節物質およびその使用

Country Status (9)

Country Link
US (2) US8193194B2 (enExample)
EP (1) EP2158183A2 (enExample)
JP (1) JP2010528035A (enExample)
CN (1) CN101687782A (enExample)
AU (1) AU2008256937A1 (enExample)
CA (1) CA2687764A1 (enExample)
MX (1) MX2009012678A (enExample)
NZ (1) NZ581309A (enExample)
WO (1) WO2008147797A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
MX2008003337A (es) * 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
EP2158183A2 (en) 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
NZ585332A (en) 2007-11-13 2012-05-25 Vertex Pharma 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
ES2377172T3 (es) * 2007-11-13 2012-03-23 Vertex Pharmaceuticals Incorporated Derivados heterocíclicos como moduladores de canales iónicos
CN101978787A (zh) * 2008-04-30 2011-02-16 夏普株式会社 照明装置和显示装置
WO2012035023A1 (en) * 2010-09-13 2012-03-22 Novartis Ag Triazine-oxadiazoles
WO2012095781A1 (en) * 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
CN104024251B (zh) 2011-10-31 2017-08-11 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
JP6038297B2 (ja) 2012-05-22 2016-12-07 ジェネンテック， インコーポレイテッド Ｎ−置換ベンズアミドおよび疼痛の処置におけるそれらの使用
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド Ｎ置換ベンズアミド及びその使用方法
IL269964B1 (en) 2013-01-31 2025-09-01 Vertex Pharma Pyridone amide compounds, compositions containing them and uses thereof
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
EP3074377B1 (en) 2013-11-27 2018-10-17 Genentech, Inc. Substituted benzamides and methods of use thereof
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
KR102364840B1 (ko) * 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
PE20180575A1 (es) 2015-05-22 2018-04-04 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas
US9771335B2 (en) * 2015-07-31 2017-09-26 The Johns Hopkins University Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
CR20180242A (es) 2015-09-28 2018-08-10 Genentech Inc Compuestos terapéuticos y sus métodos de uso
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US10954220B2 (en) 2016-03-09 2021-03-23 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
RU2638784C1 (ru) * 2016-09-14 2017-12-15 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения миофасциальных болей в мышцах шеи по Гурову-Левину
AU2017347549A1 (en) 2016-10-17 2019-05-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2024158872A1 (en) * 2023-01-25 2024-08-02 The Rockefeller University 1,3-indole-propanamide inhibitors of sars-cov-2 plpro/nsp3 and derivatives thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649347A (en) * 1979-09-21 1981-05-02 Shionogi & Co Ltd N4-phenoxyacetylsulfanyl amide and herbicide
JP2000511163A (ja) * 1996-05-29 2000-08-29 ヘキスト・シエーリング・アグレボ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 新規なｎ―アシルスルホンアミド、除草剤と解毒剤の新規な混合物およびその使用
WO2002094767A2 (en) * 2001-05-18 2002-11-28 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
JP2003321460A (ja) * 2002-02-28 2003-11-11 Takeda Chem Ind Ltd アゾール化合物
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
JP2005526714A (ja) * 2002-01-17 2005-09-08 ニューロジェン・コーポレーション カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体
WO2006011005A1 (en) * 2004-07-16 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents
WO2006066968A1 (en) * 2004-12-23 2006-06-29 Glaxo Group Limited Pyridine compounds for the treatment of prostaglandin mediated diseases

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD9688A (enExample) *
US2411495A (en) * 1938-02-02 1946-11-19 Schering Corp Valuable derivatives of sulphonamides and a method of making the same
DE840241C (de) * 1938-02-03 1952-05-29 Schering Ag Verfahren zur Herstellung von Abkoemmlingen von Sulfonamiden
GB598472A (en) * 1943-11-05 1948-02-19 Geigy Ag J R Manufacture of para-aminobenzene sulphonacylamides
GB604259A (en) * 1944-12-28 1948-06-30 Geigy Ag J R Manufacture of 4-aminobenzenesulphonyl-ureas
US2907692A (en) * 1953-02-11 1959-10-06 Boehringer & Soehne Gmbh Composition for treating diabetes and a process of administering same
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
CH435298A (fr) * 1963-10-08 1967-05-15 Gevaert Photo Prod Nv Procédé de préparation de 3-acylamino-5-pyrazolones
BE666204A (enExample) * 1964-06-30
CH459222A (de) * 1965-10-27 1968-07-15 Sandoz Ag Verfahren zur Herstellung von neuen heterocyclischen Sulfonylharnstoff-Derivaten
RO62697A2 (fr) * 1974-05-04 1978-03-15 Sintofarm Intreprinderea Derives du 2,3-dihydro-1,3-benzoxazine-2,4-dione et procede de preparation
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
DE3466986D1 (de) 1983-02-04 1987-12-03 Ciba Geigy Ag N-phenylsulfonyl-n'-pyrimidinyl- and -triazinylurea
ATE84302T1 (de) 1988-10-20 1993-01-15 Ciba Geigy Ag Sulfamoylphenylharnstoffe.
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
JPH06135940A (ja) * 1992-10-22 1994-05-17 Mitsubishi Petrochem Co Ltd 新規なハロゲン化スルホンアミド誘導体およびそれを有効成分とする除草剤
CA2110524A1 (en) * 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
US5620997A (en) * 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3050126B2 (ja) * 1996-06-11 2000-06-12 日本製紙株式会社 感熱記録体
JP2000198272A (ja) * 1998-11-04 2000-07-18 Oji Paper Co Ltd 可逆性感熱記録体
AU2004263515A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
MXPA06008606A (es) * 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
US7977322B2 (en) * 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
DE102004035132A1 (de) * 2004-07-20 2006-02-16 Bayer Cropscience Ag Insektizide Mittel auf Basis von ausgewählten Insektiziden und Safenern
MX2007014180A (es) 2005-05-10 2008-01-14 Vertex Pharma Derivados biciclicos como moduladores de canales de iones.
EP1888558B1 (en) 2005-05-16 2011-10-05 Vertex Pharmaceuticals, Inc. Bicyclic derivatives as modulators of ion channels
US7683066B2 (en) 2005-05-20 2010-03-23 Vertex Pharmaceuticals Incorporated Isoquinolines useful as modulators of ion channels
KR20080019693A (ko) 2005-06-09 2008-03-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 인단 유도체
MX2008003337A (es) 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
WO2007047474A2 (en) 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
CN101331115A (zh) 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
CN101356170B (zh) * 2005-11-08 2012-09-26 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
RU2008129821A (ru) 2005-12-21 2010-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
ES2398319T3 (es) * 2005-12-28 2013-03-15 Vertex Pharmaceuticals Incorporated Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2580803T3 (es) * 2006-04-07 2016-08-26 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2158183A2 (en) 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
NZ585332A (en) 2007-11-13 2012-05-25 Vertex Pharma 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
ES2377172T3 (es) 2007-11-13 2012-03-23 Vertex Pharmaceuticals Incorporated Derivados heterocíclicos como moduladores de canales iónicos
CA2705562C (en) * 2007-11-16 2016-05-17 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
EP2231606B1 (en) * 2007-12-07 2013-02-13 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
ES2611077T3 (es) * 2007-12-07 2017-05-04 Vertex Pharmaceuticals Incorporated Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico
NZ720282A (en) * 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
EP2271621B1 (en) * 2008-03-31 2013-11-20 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
US7846954B2 (en) 2008-07-01 2010-12-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
JP2012504143A (ja) * 2008-09-29 2012-02-16 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649347A (en) * 1979-09-21 1981-05-02 Shionogi & Co Ltd N4-phenoxyacetylsulfanyl amide and herbicide
JP2000511163A (ja) * 1996-05-29 2000-08-29 ヘキスト・シエーリング・アグレボ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 新規なｎ―アシルスルホンアミド、除草剤と解毒剤の新規な混合物およびその使用
WO2002094767A2 (en) * 2001-05-18 2002-11-28 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
JP2005526714A (ja) * 2002-01-17 2005-09-08 ニューロジェン・コーポレーション カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体
JP2003321460A (ja) * 2002-02-28 2003-11-11 Takeda Chem Ind Ltd アゾール化合物
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
WO2006011005A1 (en) * 2004-07-16 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents
WO2006066968A1 (en) * 2004-12-23 2006-06-29 Glaxo Group Limited Pyridine compounds for the treatment of prostaglandin mediated diseases

Also Published As

Publication number Publication date
US8883766B2 (en) 2014-11-11
MX2009012678A (es) 2012-09-20
EP2158183A2 (en) 2010-03-03
CA2687764A1 (en) 2008-12-04
US20080293737A1 (en) 2008-11-27
US20120208790A1 (en) 2012-08-16
WO2008147797A3 (en) 2009-07-09
US8193194B2 (en) 2012-06-05
WO2008147797A2 (en) 2008-12-04
AU2008256937A1 (en) 2008-12-04
CN101687782A (zh) 2010-03-31
NZ581309A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
US8193194B2 (en) Ion channel modulators and methods of use
US8236815B2 (en) Ion channel modulators and methods of uses
EP1891063B1 (en) Bicyclic derivatives as modulators of ion channels
US8357702B2 (en) Bicyclic derivatives as modulators of voltage gated ion channels
EP1888558B1 (en) Bicyclic derivatives as modulators of ion channels
EP1934191B1 (en) Biphenyl derivatives as modulators of voltage gated ion channels
JP2010539244A (ja) イオンチャネルのモジュレーターとしてのピリジルスルホンアミド
JP2012149084A (ja) イオンチャネルのモジュレーターとして有用なキノリン誘導体
JP2009512717A (ja) イオンチャネルを調節するための誘導体
CN101238109A (zh) 作为离子通道调节剂的茚满衍生物
JP2011503191A (ja) イオンチャネルのモジュレーターとしての複素環誘導体
JP2008540665A (ja) イオンチャネルのモジュレーターとして有用なビアリール
HK1139648A (en) Ion channel modulators and methods of use
HK1125365A (en) Biphenyl derivatives as modulators of voltage gated ion channels
HK1119433B (en) Indane derivatives as modulators of ion channels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131125